238 related articles for article (PubMed ID: 23650412)
1. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
Perez EA; Dueck AC; McCullough AE; Chen B; Geiger XJ; Jenkins RB; Lingle WL; Davidson NE; Martino S; Kaufman PA; Kutteh LA; Sledge GW; Harris LN; Gralow JR; Reinholz MM
J Clin Oncol; 2013 Jun; 31(17):2115-22. PubMed ID: 23650412
[TBL] [Abstract][Full Text] [Related]
2. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
[TBL] [Abstract][Full Text] [Related]
3. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
Dueck AC; Reinholz MM; Geiger XJ; Tenner K; Ballman K; Jenkins RB; Riehle D; Chen B; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow J; Harris LN; Ingle JN; Lingle WL; Perez EA
Clin Cancer Res; 2013 Oct; 19(20):5798-807. PubMed ID: 23965903
[TBL] [Abstract][Full Text] [Related]
4. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
[TBL] [Abstract][Full Text] [Related]
5. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
6. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2
Reinholz MM; Chen B; Dueck AC; Tenner K; Ballman K; Riehle D; Jenkins RB; Geiger XJ; McCullough AE; Perez EA
Clin Cancer Res; 2017 Aug; 23(15):4203-4211. PubMed ID: 28533226
[No Abstract] [Full Text] [Related]
7. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
Perez EA; Reinholz MM; Hillman DW; Tenner KS; Schroeder MJ; Davidson NE; Martino S; Sledge GW; Harris LN; Gralow JR; Dueck AC; Ketterling RP; Ingle JN; Lingle WL; Kaufman PA; Visscher DW; Jenkins RB
J Clin Oncol; 2010 Oct; 28(28):4307-15. PubMed ID: 20697084
[TBL] [Abstract][Full Text] [Related]
8. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Perez EA; Romond EH; Suman VJ; Jeong JH; Davidson NE; Geyer CE; Martino S; Mamounas EP; Kaufman PA; Wolmark N
J Clin Oncol; 2011 Sep; 29(25):3366-73. PubMed ID: 21768458
[TBL] [Abstract][Full Text] [Related]
9. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.
Jensen JD; Knoop A; Laenkholm AV; Grauslund M; Jensen MB; Santoni-Rugiu E; Andersson M; Ewertz M
Ann Oncol; 2012 Aug; 23(8):2034-2042. PubMed ID: 22172323
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N
J Clin Oncol; 2014 Nov; 32(33):3744-52. PubMed ID: 25332249
[TBL] [Abstract][Full Text] [Related]
12. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
Perez EA; Suman VJ; Davidson NE; Gralow JR; Kaufman PA; Visscher DW; Chen B; Ingle JN; Dakhil SR; Zujewski J; Moreno-Aspitia A; Pisansky TM; Jenkins RB
J Clin Oncol; 2011 Dec; 29(34):4491-7. PubMed ID: 22042958
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
Chumsri S; Li Z; Serie DJ; Mashadi-Hossein A; Colon-Otero G; Song N; Pogue-Geile KL; Gavin PG; Paik S; Moreno-Aspitia A; Perez EA; Thompson EA
J Clin Oncol; 2019 Dec; 37(35):3425-3435. PubMed ID: 31622131
[TBL] [Abstract][Full Text] [Related]
14. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Fehrenbacher L; Cecchini RS; Geyer CE; Rastogi P; Costantino JP; Atkins JN; Crown JP; Polikoff J; Boileau JF; Provencher L; Stokoe C; Moore TD; Robidoux A; Flynn PJ; Borges VF; Albain KS; Swain SM; Paik S; Mamounas EP; Wolmark N
J Clin Oncol; 2020 Feb; 38(5):444-453. PubMed ID: 31821109
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hashizume K; Ono M; Kouno T; Ando M; Tamura K; Katsumata N; Hasegawa T; Kinoshita T; Fujiwara Y
Med Oncol; 2009; 26(3):344-9. PubMed ID: 19016009
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
17. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.
Caparica R; Ma Y; De Angelis C; Richard F; Desmedt C; Awada A; Piccart M; Perez EA; Moreno-Aspitia A; Badve S; Thompson EA; de Azambuja E
Clin Breast Cancer; 2022 Jun; 22(4):308-318. PubMed ID: 34980541
[TBL] [Abstract][Full Text] [Related]
18. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Perez EA; Thompson EA; Ballman KV; Anderson SK; Asmann YW; Kalari KR; Eckel-Passow JE; Dueck AC; Tenner KS; Jen J; Fan JB; Geiger XJ; McCullough AE; Chen B; Jenkins RB; Sledge GW; Winer EP; Gralow JR; Reinholz MM
J Clin Oncol; 2015 Mar; 33(7):701-8. PubMed ID: 25605861
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.
Advani PP; Ballman KV; Dockter TJ; Colon-Otero G; Perez EA
J Clin Oncol; 2016 Feb; 34(6):581-7. PubMed ID: 26392097
[TBL] [Abstract][Full Text] [Related]
20. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Perez EA; Suman VJ; Davidson NE; Sledge GW; Kaufman PA; Hudis CA; Martino S; Gralow JR; Dakhil SR; Ingle JN; Winer EP; Gelmon KA; Gersh BJ; Jaffe AS; Rodeheffer RJ
J Clin Oncol; 2008 Mar; 26(8):1231-8. PubMed ID: 18250349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
